Want to see ABCL full AI Analyst Report?
Top Page
AbCellera Biologics
(NASDAQ:ABCL)
Select Model
Select Model
Rating:58Neutral
Price Target:
$12.00
▲(125.99% Upside)
Action:Reiterated
Date:08/17/26
ABCL’s score is primarily held back by weak financial performance (declining revenue, large losses, and negative free cash flow), partially offset by a strong balance sheet and the earnings-call-reinforced liquidity runway and partnership funding. Technically, the stock is in a strong uptrend versus moving averages, but extreme overbought readings increase near-term volatility risk. Valuation is also a drag due to negative earnings (negative P/E) and no dividend yield support in the provided data.
Positive Factors
Strong liquidity runway
Substantial cash, government funding and at least three years of planned pipeline support reduce near-term financing risk. This gives AbCellera flexibility to fund clinical programs and platform investment while pursuing partnerships.
Negative Factors
Declining revenue and deep losses
Falling revenue alongside very large operating losses shows that the current cost base is not supported by recurring business activity. Sustained losses could weaken capital efficiency and increase dependence on financing, milestones or successful pipeline outcomes.
Read all positive and negative factors
Positive Factors
Negative Factors
Strong liquidity runway
Substantial cash, government funding and at least three years of planned pipeline support reduce near-term financing risk. This gives AbCellera flexibility to fund clinical programs and platform investment while pursuing partnerships.
Read all positive factors
AbCellera Biologics Key Performance Indicators (KPIs)
Any
Number of Discovery Partners
Indicates the breadth of AbCellera's collaborative network, highlighting potential for diverse innovation and revenue streams through partnerships.
Indicates the breadth of AbCellera's collaborative network, highlighting potential for diverse innovation and revenue streams through partnerships.
Data provided by:
The Fly
The FlyAbCellera Biologics (ABCL) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$3.49B
Dividend YieldN/A
Average Volume (3M)6.63M
Price to Earnings (P/E)―
Beta (1Y)1.87
Revenue Growth101.28%
EPS Growth2.49%
CountryUS
Employees562
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.54
Shares Outstanding324,047,360
10 Day Avg. Volume4,701,846
30 Day Avg. Volume6,632,648
Financial Highlights & Ratios
PEG Ratio0.64
Price to Book (P/B)1.06
Price to Sales (P/S)13.60
P/FCF Ratio-5.87
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$17.17Price Target Upside223.29% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering7
EPS Forecast (FY)-0.66
Revenue Forecast (FY)$25.25M
AbCellera Biologics Business Overview & Revenue Model
Company Description
AbCellera Biologics Inc. specializes in pioneering an advanced platform for the discovery of antibodies. This comprehensive, AI-driven system meticulously explores and analyzes natural immune systems to identify antibodies suitable for the creatio...
How the Company Makes Money
AbCellera primarily makes money by providing antibody discovery and early development services through partnered programs with pharmaceutical and biotechnology companies. Under these collaborations, AbCellera can earn: (1) upfront payments when a ...
AbCellera Biologics Earnings Call Summary
Earnings Call Date:Aug 05, 2026
(Q2-2026)
| % Change Since: |
Next Earnings Date:Nov 10, 2026
Earnings Call Sentiment Positive
The call conveys a cautiously optimistic outlook: the company is well capitalized with substantial upfront partnership cash, large potential deal value, and multiple near-term clinical catalysts (notably ABCL635 topline readout and ABCL575 Phase I readout). Those positives are tempered by a sharp year-over-year revenue decline (~-76.5%), a wider net loss (+57.1%), increased R&D spend, and remaining scientific and placebo-related risks for the lead program. On balance, the strong liquidity position and strategic partnerships alongside clear near-term catalysts outweigh the financial pressures and programmatic risks in the short term.Positive Updates
Strong liquidity and runway
Cash and equivalents of $567M at quarter end, plus ~ $110M in available committed government funding, yielding over $675M in available liquidity to execute the strategy and fund at least ~3 years of pipeline investments.
Negative Updates
Sharp quarter-over-quarter revenue decline
Revenue fell to ~$4M in Q2 2026 from ~$17M in Q2 2025, a decline of approximately -76.5%, with current quarter revenue comprised mostly of research fees.
Read all updates
Q2-2026 Updates
Positive
Negative
Strong liquidity and runway
Cash and equivalents of $567M at quarter end, plus ~ $110M in available committed government funding, yielding over $675M in available liquidity to execute the strategy and fund at least ~3 years of pipeline investments.
Read all positive updates
Company Guidance
Management guided that a top‑line readout for ABCL635 (postmenopausal VMS) is expected "very soon" after enrollment and initial dosing completed in June, with the Phase II top‑line reporting 4‑week data only (single dose, no re‑dosing) and they’re targeting a clinically meaningful frequency improvement of roughly 20% vs placebo and ≥2 fewer hot flashes/day; ABCL575 Phase I dosing is complete with a readout on track for Q4 (no plans to develop beyond Phase I), ABCL‑688 and ABCL386 are expected to enter Phase I/II in 2027, and one planned IND‑enabling move in H1 was missed but progress continues. Financial guidance/metrics: Q2 revenue ≈$4M (vs ≈$17M y/y), R&D ≈$46M (up ≈$7M y/y), SG&A ≈$14M (down from $22M), net loss ≈$55M (vs $35M) and loss per share $0.18; cash and marketable securities ≈$565–567M with $420M invested in short‑term securities, roughly $110M of available committed government funding (total available liquidity >$675M including unused government funding), operating cash used ≈$8M in H1 (including $56M upfront from Jazz), YTD capex ≈$6M, $7M in government grants received, and $15M invested in marketable securities this quarter. Strategic deal metrics: recent TCE collaborations bring $28M upfront from Vertex and $84M near‑term from Jazz (total >$110M upfront), $56M of Jazz upfront received to date with another $28M due, potential Jazz downstream payments >$2B and total program deal value >$4B, plus mid‑single to low‑double‑digit tiered royalties; management says liquidity supports at least the next 3 years of pipeline investment.AbCellera Biologics Financial Statement Overview
Summary
Income Statement
26
Negative
Balance Sheet
70
Positive
Cash Flow
32
Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 66.17M | 75.13M | 28.83M | 38.02M | 485.42M | 375.20M |
| Gross Profit | 49.60M | 46.31M | 28.83M | 38.02M | 418.99M | 329.69M |
| EBITDA | -160.30M | -148.77M | -204.15M | -192.16M | 260.17M | 239.15M |
| Net Income | -164.66M | -146.41M | -162.86M | -146.40M | 158.52M | 153.46M |
Balance Sheet | ||||||
| Total Assets | 1.31B | 1.36B | 1.36B | 1.49B | 1.54B | 1.32B |
| Cash, Cash Equivalents and Short-Term Investments | 540.10M | 533.83M | 625.61M | 760.59M | 886.49M | 722.98M |
| Total Debt | 135.62M | 143.22M | 65.36M | 77.38M | 82.26M | 40.06M |
| Total Liabilities | 411.56M | 390.05M | 304.47M | 335.78M | 307.63M | 292.84M |
| Stockholders Equity | 896.02M | 966.90M | 1.06B | 1.15B | 1.23B | 1.03B |
Cash Flow | ||||||
| Free Cash Flow | -179.46M | -174.07M | -186.95M | -121.38M | 204.70M | 186.13M |
| Operating Cash Flow | -154.72M | -131.29M | -108.56M | -43.88M | 277.36M | 244.58M |
| Investing Cash Flow | 97.89M | 87.75M | 121.41M | -221.11M | -352.63M | -332.25M |
| Financing Cash Flow | 32.26M | 14.08M | 12.77M | 10.36M | -1.63M | -3.89M |
AbCellera Biologics Technical Analysis
Positive
5.31
Price Trends
6.72
Positive
5.55
Positive
4.64
Positive
Market Momentum
1.24
Negative
81.38
Negative
96.28
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ABCL, the sentiment is Positive. The current price of 5.31 is below the 20-day moving average (MA) of 7.22, below the 50-day MA of 6.72, and above the 200-day MA of 4.64, indicating a bullish trend. The MACD of 1.24 indicates Negative momentum. The RSI at 81.38 is Negative, neither overbought nor oversold. The STOCH value of 96.28 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for ABCL.
AbCellera Biologics Risk Analysis
AbCellera Biologics disclosed 99 risk factors in its most recent earnings report. AbCellera Biologics reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
AbCellera Biologics Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
66 Neutral | $4.80B | -23.81 | -39.01% | ― | ― | -18.88% | |
58 Neutral | $3.49B | -20.74 | -17.49% | ― | 101.28% | 2.49% | |
58 Neutral | $6.49B | -883.54 | -3.51% | ― | -60.77% | -27.57% | |
57 Neutral | $3.89B | -17.74 | -16.91% | ― | ― | 1.47% | |
54 Neutral | $3.75B | -7.52 | -87.98% | ― | -55.34% | -23.18% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
50 Neutral | $1.77B | -7.84 | -372.94% | ― | 222.65% | 35.43% |
* Healthcare Sector Average
ABCL
AbCellera Biologics
11.20
6.91
161.07%
SNDX
Syndax Pharmaceuticals
19.76
4.37
28.35%
RCUS
Arcus Biosciences
29.56
19.50
193.84%
DNTH
Dianthus Therapeutics
114.86
92.16
405.99%
EWTX
Edgewise Therapeutics
44.04
30.24
219.13%
GPCR
Structure Therapeutics, Inc. Sponsored ADR
53.76
34.96
185.96%
AbCellera Biologics Corporate Events
Business Operations and StrategyPrivate Placements and Financing
AbCellera Biologics Announces Oversubscribed $200 Million Offering
Positive
Aug 13, 2026
On August 12, 2026, AbCellera Biologics Inc. priced an oversubscribed underwritten public offering of 17,435,897 common shares at $9.75 each and pre-funded warrants for 3,076,926 common shares at $9.74999 each, for expected gross proceeds of about...
Business Operations and StrategyProduct-Related Announcements
AbCellera to Report Phase 2 Menopause Therapy Data
Positive
Aug 7, 2026
On August 7, 2026, AbCellera announced it will release top-line data from its Phase 2 trial of ABCL635, an investigational non-hormonal antibody treatment for moderate-to-severe vasomotor symptoms due to menopause, before markets open on Monday, A...
Business Operations and Strategy
AbCellera and Vertex launch autoimmune T-cell engager partnership
Positive
Jul 29, 2026
On July 29, 2026, AbCellera Biologics announced a collaboration with Vertex Pharmaceuticals to research, develop, manufacture, and commercialize multispecific T-cell engagers for autoimmune diseases and other conditions. AbCellera will lead discov...
Business Operations and StrategyExecutive/Board Changes
AbCellera Biologics Adds Independent Director to Board
Positive
Jul 6, 2026
On June 30, 2026, AbCellera Biologics Inc. appointed Lynn Seely, M.D., as an independent Class III director to its Board, with her term running until the 2029 annual meeting of shareholders. The Board determined she meets Nasdaq independence stand...
Business Operations and Strategy
AbCellera, Jazz Partner on Next-Generation Cancer Antibodies
Positive
Jun 17, 2026
On June 17, 2026, Jazz Pharmaceuticals and AbCellera Biologics announced a preclinical research collaboration, option and license agreement to discover and develop next-generation T-cell engaging multispecific antibodies for multiple gastrointesti...
Executive/Board ChangesShareholder Meetings
AbCellera Shareholders Back Directors, Auditors, Executive Pay
Positive
Jun 12, 2026
AbCellera Biologics Inc. held its Annual Meeting of Shareholders on June 11, 2026, with 305,264,947 common shares eligible to vote as of the April 15, 2026 record date. Shareholders approved the election of Class III directors John S. Montalbano a...
Business Operations and StrategyExecutive/Board Changes
AbCellera Biologics Adds Victor Sandor to Board
Positive
Jun 5, 2026
On June 1, 2026, AbCellera Biologics appointed medical oncologist Victor Sandor to its board of directors as an independent director, with his term running until the next annual shareholders’ meeting. The Nasdaq-listed company said Sandor wi...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.